We want to ensure optimum use of our website for you, and to continually improve our website. Therefore, we work with selected partners (e.g. Pardot). You can revoke your voluntary consent at any time. You can find further information and setting options under „Configure“ and in our data protection information.
Elekta will publish its interim report for May-July 2012/13 on September 4 as per:
· The report will be published at approximately 13:00 CET.
· Elekta will host a telephone conference at 13:45-14:30 CET, with Tomas Puusepp, President and CEO and Håkan Bergström, CFO.
To take part in the conference call, please dial in 5-10 minutes in advance and use the access code: 920990
· UK dial-in number: +44 (0)207 162 00 77
· US dial-in number: +1 334 323 62 01
· Swedish dial-in number: +46 (0)8 505 201 10
The telephone conference will also be broadcasted live online (audio only and without the possibility to ask questions). Please use this link: http://webeventservices.reg.meeting-stream.com/67238_elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.